<DOC>
	<DOCNO>NCT01949103</DOCNO>
	<brief_summary>TD-1607 , administer intravenously multiple ascend dos , investigate healthy subject assess tolerability , safety , pharmacokinetics .</brief_summary>
	<brief_title>TD-1607 MAD Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Subject healthy nonsmoking male female ( nonchildbearing potential ) 18 55 year old , inclusive , Screening . Subject body mass index ( BMI ) 19 30 kg/m2 , inclusive , weigh least 50 kg . Subject clinically significant abnormality result laboratory evaluation Screening Day 1 . Subject evidence history clinically significant , relevant hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological , allergic disease ( except untreated , asymptomatic seasonal allergy time dose ) . Subject history allergy hypersensitivity glycopeptide ( e.g. , vancomycin ) betalactam ( e.g. , penicillin cephalosporin ) antibiotic . Subject participate another clinical trial investigational drug ( medical device ) within 60 day ( 5 halflives , whichever long ) prior Screening currently participate another trial investigational drug ( medical device ) . Subject previously participate trial TD1607 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gram-positive</keyword>
</DOC>